抗高尿酸血症薬のグローバル市場インサイト・予測（～2028年）

• 英文タイトル：Global Antihyperuricemic Agents Market Insights, Forecast to 2028

• レポートコード：QY2207E10359 • 出版社/出版日：QYResearch / 2022年7月 • レポート形態：英文、PDF、128ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥735,000 (USD4,900)	▷ お問い合わせ
Multi User	￥1,102,500 (USD7,350)	▷ お問い合わせ
Enterprise License	￥1,470,000 (USD9,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

新型コロナウイルス感染症のパンデミックにより、世界の抗高尿酸血症薬の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に抗高尿酸血症薬の世界市場のxxx％を占める「尿酸生成抑制剤」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「病院薬局」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 中国の抗高尿酸血症薬の市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの抗高尿酸血症薬市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの抗高尿酸血症薬市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 抗高尿酸血症薬のグローバル主要メーカーには、Takeda Pharmaceuticals、Hikma、Wockhardt、West Ward Pharmaceuticals、Rhea Pharmaceutical、Medinova、Odan Laboratories、TEIJIN、Casper Pharma、Dr. Reddys Laboratories、Teva、Zydus Pharmaceuticals、Mylan、Sun Pharmaceutical、APOTEX、NorthStar Healthcare、Ipca Laboratories、Accord Healthcare、Gentec Pharmaceutical Group、Indoco Remedies、Lupin、Waterstone Pharmaceuticals、ALP Pharm、Jiangsu Hengrui Medicine、Jiangsu Wanbang Biopharmaceuticals、Hangzhou Zhuyangxin Pharmaceutical、YiChang HEC ChangJiang Pharmaceutical、KPC Pharmaceuticals、Tonghua Limin、Beijing Jialin Pharmaceuticalなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 抗高尿酸血症薬市場は、種類と用途によって区分されます。世界の抗高尿酸血症薬市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。 【種類別セグメント】 尿酸生成抑制剤、尿酸排泄促進剤、その他 【用途別セグメント】 病院薬局、小売薬局、オンライン薬局 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 抗高尿酸血症薬製品概要 - 種類別市場（尿酸生成抑制剤、尿酸排泄促進剤、その他） - 用途別市場（病院薬局、小売薬局、オンライン薬局） - 調査の目的 ・エグゼクティブサマリー - 世界の抗高尿酸血症薬販売量予測2017-2028 - 世界の抗高尿酸血症薬売上予測2017-2028 - 抗高尿酸血症薬の地域別販売量 - 抗高尿酸血症薬の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別抗高尿酸血症薬販売量 - 主要メーカー別抗高尿酸血症薬売上 - 主要メーカー別抗高尿酸血症薬価格 - 競争状況の分析 - 企業M&A動向 ・種類別市場規模（尿酸生成抑制剤、尿酸排泄促進剤、その他） - 抗高尿酸血症薬の種類別販売量 - 抗高尿酸血症薬の種類別売上 - 抗高尿酸血症薬の種類別価格 ・用途別市場規模（病院薬局、小売薬局、オンライン薬局） - 抗高尿酸血症薬の用途別販売量 - 抗高尿酸血症薬の用途別売上 - 抗高尿酸血症薬の用途別価格 ・北米市場 - 北米の抗高尿酸血症薬市場規模（種類別、用途別） - 主要国別の抗高尿酸血症薬市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの抗高尿酸血症薬市場規模（種類別、用途別） - 主要国別の抗高尿酸血症薬市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の抗高尿酸血症薬市場規模（種類別、用途別） - 主要国別の抗高尿酸血症薬市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の抗高尿酸血症薬市場規模（種類別、用途別） - 主要国別の抗高尿酸血症薬市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの抗高尿酸血症薬市場規模（種類別、用途別） - 主要国別の抗高尿酸血症薬市場規模（トルコ、サウジアラビア） ・企業情報 Takeda Pharmaceuticals、Hikma、Wockhardt、West Ward Pharmaceuticals、Rhea Pharmaceutical、Medinova、Odan Laboratories、TEIJIN、Casper Pharma、Dr. Reddys Laboratories、Teva、Zydus Pharmaceuticals、Mylan、Sun Pharmaceutical、APOTEX、NorthStar Healthcare、Ipca Laboratories、Accord Healthcare、Gentec Pharmaceutical Group、Indoco Remedies、Lupin、Waterstone Pharmaceuticals、ALP Pharm、Jiangsu Hengrui Medicine、Jiangsu Wanbang Biopharmaceuticals、Hangzhou Zhuyangxin Pharmaceutical、YiChang HEC ChangJiang Pharmaceutical、KPC Pharmaceuticals、Tonghua Limin、Beijing Jialin Pharmaceutical ・産業チェーン及び販売チャネル分析 - 抗高尿酸血症薬の産業チェーン分析 - 抗高尿酸血症薬の原材料 - 抗高尿酸血症薬の生産プロセス - 抗高尿酸血症薬の販売及びマーケティング - 抗高尿酸血症薬の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 抗高尿酸血症薬の産業動向 - 抗高尿酸血症薬のマーケットドライバー - 抗高尿酸血症薬の課題 - 抗高尿酸血症薬の阻害要因 ・主な調査結果

Antihyperuricemic agents are also called anti-gout drugs. These drugs correct the overproduction or underexcretion of uric acid.
Market Analysis and Insights: Global Antihyperuricemic Agents Market
Due to the COVID-19 pandemic, the global Antihyperuricemic Agents market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, Inhibit Uric Acid Production Agents accounting for % of the Antihyperuricemic Agents global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital Pharmacies segment is altered to an % CAGR throughout this forecast period.
China Antihyperuricemic Agents market size is valued at US$ million in 2021, while the US and Europe Antihyperuricemic Agents are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Antihyperuricemic Agents landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
The global key manufacturers of Antihyperuricemic Agents include Takeda Pharmaceuticals, Hikma, Wockhardt, West Ward Pharmaceuticals, Rhea Pharmaceutical, Medinova, Odan Laboratories, TEIJIN and Casper Pharma, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Antihyperuricemic Agents Scope and Segment
Antihyperuricemic Agents market is segmented by Type and by Distribution Channel. Players, stakeholders, and other participants in the global Antihyperuricemic Agents market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Distribution Channel for the period 2017-2028.
Segment by Type
Inhibit Uric Acid Production Agents
Promote Uric Acid Excretion Agents
Others
Segment by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Company
Takeda Pharmaceuticals
Hikma
Wockhardt
West Ward Pharmaceuticals
Rhea Pharmaceutical
Medinova
Odan Laboratories
TEIJIN
Casper Pharma
Dr. Reddys Laboratories
Teva
Zydus Pharmaceuticals
Mylan
Sun Pharmaceutical
APOTEX
NorthStar Healthcare
Ipca Laboratories
Accord Healthcare
Gentec Pharmaceutical Group
Indoco Remedies
Lupin
Waterstone Pharmaceuticals
ALP Pharm
Jiangsu Hengrui Medicine
Jiangsu Wanbang Biopharmaceuticals
Hangzhou Zhuyangxin Pharmaceutical
YiChang HEC ChangJiang Pharmaceutical
KPC Pharmaceuticals
Tonghua Limin
Beijing Jialin Pharmaceutical
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

レポート目次

---

1 Study Coverage
1.1 Antihyperuricemic Agents Product Introduction
1.2 Market by Type
1.2.1 Global Antihyperuricemic Agents Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Inhibit Uric Acid Production Agents
1.2.3 Promote Uric Acid Excretion Agents
1.2.4 Others
1.3 Market by Distribution Channel
1.3.1 Global Antihyperuricemic Agents Market Size Growth Rate by Distribution Channel, 2017 VS 2021 VS 2028
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Antihyperuricemic Agents Sales Estimates and Forecasts 2017-2028
2.2 Global Antihyperuricemic Agents Revenue Estimates and Forecasts 2017-2028
2.3 Global Antihyperuricemic Agents Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Antihyperuricemic Agents Sales by Region
2.4.1 Global Antihyperuricemic Agents Sales by Region (2017-2022)
2.4.2 Global Sales Antihyperuricemic Agents by Region (2023-2028)
2.5 Global Antihyperuricemic Agents Revenue by Region
2.5.1 Global Antihyperuricemic Agents Revenue by Region (2017-2022)
2.5.2 Global Antihyperuricemic Agents Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Antihyperuricemic Agents Sales by Manufacturers
3.1.1 Global Top Antihyperuricemic Agents Manufacturers by Sales (2017-2022)
3.1.2 Global Antihyperuricemic Agents Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Antihyperuricemic Agents in 2021
3.2 Global Antihyperuricemic Agents Revenue by Manufacturers
3.2.1 Global Antihyperuricemic Agents Revenue by Manufacturers (2017-2022)
3.2.2 Global Antihyperuricemic Agents Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Antihyperuricemic Agents Revenue in 2021
3.3 Global Antihyperuricemic Agents Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Antihyperuricemic Agents Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Antihyperuricemic Agents Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Antihyperuricemic Agents Sales by Type
4.1.1 Global Antihyperuricemic Agents Historical Sales by Type (2017-2022)
4.1.2 Global Antihyperuricemic Agents Forecasted Sales by Type (2023-2028)
4.1.3 Global Antihyperuricemic Agents Sales Market Share by Type (2017-2028)
4.2 Global Antihyperuricemic Agents Revenue by Type
4.2.1 Global Antihyperuricemic Agents Historical Revenue by Type (2017-2022)
4.2.2 Global Antihyperuricemic Agents Forecasted Revenue by Type (2023-2028)
4.2.3 Global Antihyperuricemic Agents Revenue Market Share by Type (2017-2028)
4.3 Global Antihyperuricemic Agents Price by Type
4.3.1 Global Antihyperuricemic Agents Price by Type (2017-2022)
4.3.2 Global Antihyperuricemic Agents Price Forecast by Type (2023-2028)
5 Market Size by Distribution Channel
5.1 Global Antihyperuricemic Agents Sales by Distribution Channel
5.1.1 Global Antihyperuricemic Agents Historical Sales by Distribution Channel (2017-2022)
5.1.2 Global Antihyperuricemic Agents Forecasted Sales by Distribution Channel (2023-2028)
5.1.3 Global Antihyperuricemic Agents Sales Market Share by Distribution Channel (2017-2028)
5.2 Global Antihyperuricemic Agents Revenue by Distribution Channel
5.2.1 Global Antihyperuricemic Agents Historical Revenue by Distribution Channel (2017-2022)
5.2.2 Global Antihyperuricemic Agents Forecasted Revenue by Distribution Channel (2023-2028)
5.2.3 Global Antihyperuricemic Agents Revenue Market Share by Distribution Channel (2017-2028)
5.3 Global Antihyperuricemic Agents Price by Distribution Channel
5.3.1 Global Antihyperuricemic Agents Price by Distribution Channel (2017-2022)
5.3.2 Global Antihyperuricemic Agents Price Forecast by Distribution Channel (2023-2028)
6 North America
6.1 North America Antihyperuricemic Agents Market Size by Type
6.1.1 North America Antihyperuricemic Agents Sales by Type (2017-2028)
6.1.2 North America Antihyperuricemic Agents Revenue by Type (2017-2028)
6.2 North America Antihyperuricemic Agents Market Size by Distribution Channel
6.2.1 North America Antihyperuricemic Agents Sales by Distribution Channel (2017-2028)
6.2.2 North America Antihyperuricemic Agents Revenue by Distribution Channel (2017-2028)
6.3 North America Antihyperuricemic Agents Market Size by Country
6.3.1 North America Antihyperuricemic Agents Sales by Country (2017-2028)
6.3.2 North America Antihyperuricemic Agents Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Antihyperuricemic Agents Market Size by Type
7.1.1 Europe Antihyperuricemic Agents Sales by Type (2017-2028)
7.1.2 Europe Antihyperuricemic Agents Revenue by Type (2017-2028)
7.2 Europe Antihyperuricemic Agents Market Size by Distribution Channel
7.2.1 Europe Antihyperuricemic Agents Sales by Distribution Channel (2017-2028)
7.2.2 Europe Antihyperuricemic Agents Revenue by Distribution Channel (2017-2028)
7.3 Europe Antihyperuricemic Agents Market Size by Country
7.3.1 Europe Antihyperuricemic Agents Sales by Country (2017-2028)
7.3.2 Europe Antihyperuricemic Agents Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Antihyperuricemic Agents Market Size by Type
8.1.1 Asia Pacific Antihyperuricemic Agents Sales by Type (2017-2028)
8.1.2 Asia Pacific Antihyperuricemic Agents Revenue by Type (2017-2028)
8.2 Asia Pacific Antihyperuricemic Agents Market Size by Distribution Channel
8.2.1 Asia Pacific Antihyperuricemic Agents Sales by Distribution Channel (2017-2028)
8.2.2 Asia Pacific Antihyperuricemic Agents Revenue by Distribution Channel (2017-2028)
8.3 Asia Pacific Antihyperuricemic Agents Market Size by Region
8.3.1 Asia Pacific Antihyperuricemic Agents Sales by Region (2017-2028)
8.3.2 Asia Pacific Antihyperuricemic Agents Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Antihyperuricemic Agents Market Size by Type
9.1.1 Latin America Antihyperuricemic Agents Sales by Type (2017-2028)
9.1.2 Latin America Antihyperuricemic Agents Revenue by Type (2017-2028)
9.2 Latin America Antihyperuricemic Agents Market Size by Distribution Channel
9.2.1 Latin America Antihyperuricemic Agents Sales by Distribution Channel (2017-2028)
9.2.2 Latin America Antihyperuricemic Agents Revenue by Distribution Channel (2017-2028)
9.3 Latin America Antihyperuricemic Agents Market Size by Country
9.3.1 Latin America Antihyperuricemic Agents Sales by Country (2017-2028)
9.3.2 Latin America Antihyperuricemic Agents Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
9.3.6 Colombia
10 Middle East and Africa
10.1 Middle East and Africa Antihyperuricemic Agents Market Size by Type
10.1.1 Middle East and Africa Antihyperuricemic Agents Sales by Type (2017-2028)
10.1.2 Middle East and Africa Antihyperuricemic Agents Revenue by Type (2017-2028)
10.2 Middle East and Africa Antihyperuricemic Agents Market Size by Distribution Channel
10.2.1 Middle East and Africa Antihyperuricemic Agents Sales by Distribution Channel (2017-2028)
10.2.2 Middle East and Africa Antihyperuricemic Agents Revenue by Distribution Channel (2017-2028)
10.3 Middle East and Africa Antihyperuricemic Agents Market Size by Country
10.3.1 Middle East and Africa Antihyperuricemic Agents Sales by Country (2017-2028)
10.3.2 Middle East and Africa Antihyperuricemic Agents Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Takeda Pharmaceuticals
11.1.1 Takeda Pharmaceuticals Corporation Information
11.1.2 Takeda Pharmaceuticals Overview
11.1.3 Takeda Pharmaceuticals Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Takeda Pharmaceuticals Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Takeda Pharmaceuticals Recent Developments
11.2 Hikma
11.2.1 Hikma Corporation Information
11.2.2 Hikma Overview
11.2.3 Hikma Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Hikma Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Hikma Recent Developments
11.3 Wockhardt
11.3.1 Wockhardt Corporation Information
11.3.2 Wockhardt Overview
11.3.3 Wockhardt Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Wockhardt Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Wockhardt Recent Developments
11.4 West Ward Pharmaceuticals
11.4.1 West Ward Pharmaceuticals Corporation Information
11.4.2 West Ward Pharmaceuticals Overview
11.4.3 West Ward Pharmaceuticals Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 West Ward Pharmaceuticals Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 West Ward Pharmaceuticals Recent Developments
11.5 Rhea Pharmaceutical
11.5.1 Rhea Pharmaceutical Corporation Information
11.5.2 Rhea Pharmaceutical Overview
11.5.3 Rhea Pharmaceutical Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Rhea Pharmaceutical Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Rhea Pharmaceutical Recent Developments
11.6 Medinova
11.6.1 Medinova Corporation Information
11.6.2 Medinova Overview
11.6.3 Medinova Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Medinova Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Medinova Recent Developments
11.7 Odan Laboratories
11.7.1 Odan Laboratories Corporation Information
11.7.2 Odan Laboratories Overview
11.7.3 Odan Laboratories Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Odan Laboratories Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Odan Laboratories Recent Developments
11.8 TEIJIN
11.8.1 TEIJIN Corporation Information
11.8.2 TEIJIN Overview
11.8.3 TEIJIN Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 TEIJIN Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 TEIJIN Recent Developments
11.9 Casper Pharma
11.9.1 Casper Pharma Corporation Information
11.9.2 Casper Pharma Overview
11.9.3 Casper Pharma Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Casper Pharma Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Casper Pharma Recent Developments
11.10 Dr. Reddys Laboratories
11.10.1 Dr. Reddys Laboratories Corporation Information
11.10.2 Dr. Reddys Laboratories Overview
11.10.3 Dr. Reddys Laboratories Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Dr. Reddys Laboratories Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Dr. Reddys Laboratories Recent Developments
11.11 Teva
11.11.1 Teva Corporation Information
11.11.2 Teva Overview
11.11.3 Teva Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Teva Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Teva Recent Developments
11.12 Zydus Pharmaceuticals
11.12.1 Zydus Pharmaceuticals Corporation Information
11.12.2 Zydus Pharmaceuticals Overview
11.12.3 Zydus Pharmaceuticals Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Zydus Pharmaceuticals Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Zydus Pharmaceuticals Recent Developments
11.13 Mylan
11.13.1 Mylan Corporation Information
11.13.2 Mylan Overview
11.13.3 Mylan Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Mylan Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Mylan Recent Developments
11.14 Sun Pharmaceutical
11.14.1 Sun Pharmaceutical Corporation Information
11.14.2 Sun Pharmaceutical Overview
11.14.3 Sun Pharmaceutical Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Sun Pharmaceutical Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Sun Pharmaceutical Recent Developments
11.15 APOTEX
11.15.1 APOTEX Corporation Information
11.15.2 APOTEX Overview
11.15.3 APOTEX Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 APOTEX Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 APOTEX Recent Developments
11.16 NorthStar Healthcare
11.16.1 NorthStar Healthcare Corporation Information
11.16.2 NorthStar Healthcare Overview
11.16.3 NorthStar Healthcare Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.16.4 NorthStar Healthcare Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 NorthStar Healthcare Recent Developments
11.17 Ipca Laboratories
11.17.1 Ipca Laboratories Corporation Information
11.17.2 Ipca Laboratories Overview
11.17.3 Ipca Laboratories Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.17.4 Ipca Laboratories Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.17.5 Ipca Laboratories Recent Developments
11.18 Accord Healthcare
11.18.1 Accord Healthcare Corporation Information
11.18.2 Accord Healthcare Overview
11.18.3 Accord Healthcare Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.18.4 Accord Healthcare Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.18.5 Accord Healthcare Recent Developments
11.19 Gentec Pharmaceutical Group
11.19.1 Gentec Pharmaceutical Group Corporation Information
11.19.2 Gentec Pharmaceutical Group Overview
11.19.3 Gentec Pharmaceutical Group Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.19.4 Gentec Pharmaceutical Group Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.19.5 Gentec Pharmaceutical Group Recent Developments
11.20 Indoco Remedies
11.20.1 Indoco Remedies Corporation Information
11.20.2 Indoco Remedies Overview
11.20.3 Indoco Remedies Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.20.4 Indoco Remedies Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.20.5 Indoco Remedies Recent Developments
11.21 Lupin
11.21.1 Lupin Corporation Information
11.21.2 Lupin Overview
11.21.3 Lupin Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.21.4 Lupin Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.21.5 Lupin Recent Developments
11.22 Waterstone Pharmaceuticals
11.22.1 Waterstone Pharmaceuticals Corporation Information
11.22.2 Waterstone Pharmaceuticals Overview
11.22.3 Waterstone Pharmaceuticals Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.22.4 Waterstone Pharmaceuticals Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.22.5 Waterstone Pharmaceuticals Recent Developments
11.23 ALP Pharm
11.23.1 ALP Pharm Corporation Information
11.23.2 ALP Pharm Overview
11.23.3 ALP Pharm Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.23.4 ALP Pharm Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.23.5 ALP Pharm Recent Developments
11.24 Jiangsu Hengrui Medicine
11.24.1 Jiangsu Hengrui Medicine Corporation Information
11.24.2 Jiangsu Hengrui Medicine Overview
11.24.3 Jiangsu Hengrui Medicine Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.24.4 Jiangsu Hengrui Medicine Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.24.5 Jiangsu Hengrui Medicine Recent Developments
11.25 Jiangsu Wanbang Biopharmaceuticals
11.25.1 Jiangsu Wanbang Biopharmaceuticals Corporation Information
11.25.2 Jiangsu Wanbang Biopharmaceuticals Overview
11.25.3 Jiangsu Wanbang Biopharmaceuticals Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.25.4 Jiangsu Wanbang Biopharmaceuticals Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.25.5 Jiangsu Wanbang Biopharmaceuticals Recent Developments
11.26 Hangzhou Zhuyangxin Pharmaceutical
11.26.1 Hangzhou Zhuyangxin Pharmaceutical Corporation Information
11.26.2 Hangzhou Zhuyangxin Pharmaceutical Overview
11.26.3 Hangzhou Zhuyangxin Pharmaceutical Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.26.4 Hangzhou Zhuyangxin Pharmaceutical Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.26.5 Hangzhou Zhuyangxin Pharmaceutical Recent Developments
11.27 YiChang HEC ChangJiang Pharmaceutical
11.27.1 YiChang HEC ChangJiang Pharmaceutical Corporation Information
11.27.2 YiChang HEC ChangJiang Pharmaceutical Overview
11.27.3 YiChang HEC ChangJiang Pharmaceutical Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.27.4 YiChang HEC ChangJiang Pharmaceutical Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.27.5 YiChang HEC ChangJiang Pharmaceutical Recent Developments
11.28 KPC Pharmaceuticals
11.28.1 KPC Pharmaceuticals Corporation Information
11.28.2 KPC Pharmaceuticals Overview
11.28.3 KPC Pharmaceuticals Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.28.4 KPC Pharmaceuticals Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.28.5 KPC Pharmaceuticals Recent Developments
11.29 Tonghua Limin
11.29.1 Tonghua Limin Corporation Information
11.29.2 Tonghua Limin Overview
11.29.3 Tonghua Limin Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.29.4 Tonghua Limin Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.29.5 Tonghua Limin Recent Developments
11.30 Beijing Jialin Pharmaceutical
11.30.1 Beijing Jialin Pharmaceutical Corporation Information
11.30.2 Beijing Jialin Pharmaceutical Overview
11.30.3 Beijing Jialin Pharmaceutical Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2017-2022)
11.30.4 Beijing Jialin Pharmaceutical Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.30.5 Beijing Jialin Pharmaceutical Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Antihyperuricemic Agents Industry Chain Analysis
12.2 Antihyperuricemic Agents Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Antihyperuricemic Agents Production Mode & Process
12.4 Antihyperuricemic Agents Sales and Marketing
12.4.1 Antihyperuricemic Agents Sales Channels
12.4.2 Antihyperuricemic Agents Distributors
12.5 Antihyperuricemic Agents Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Antihyperuricemic Agents Industry Trends
13.2 Antihyperuricemic Agents Market Drivers
13.3 Antihyperuricemic Agents Market Challenges
13.4 Antihyperuricemic Agents Market Restraints
14 Key Findings in The Global Antihyperuricemic Agents Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Tables
Table 1. Global Antihyperuricemic Agents Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Inhibit Uric Acid Production Agents
Table 3. Major Manufacturers of Promote Uric Acid Excretion Agents
Table 4. Major Manufacturers of Others
Table 5. Global Antihyperuricemic Agents Market Size Growth Rate by Distribution Channel, 2017 VS 2021 VS 2028 (US$ Million)
Table 6. Global Antihyperuricemic Agents Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 7. Global Antihyperuricemic Agents Sales by Region (2017-2022) & (K Units)
Table 8. Global Antihyperuricemic Agents Sales Market Share by Region (2017-2022)
Table 9. Global Antihyperuricemic Agents Sales by Region (2023-2028) & (K Units)
Table 10. Global Antihyperuricemic Agents Sales Market Share by Region (2023-2028)
Table 11. Global Antihyperuricemic Agents Revenue by Region (2017-2022) & (US$ Million)
Table 12. Global Antihyperuricemic Agents Revenue Market Share by Region (2017-2022)
Table 13. Global Antihyperuricemic Agents Revenue by Region (2023-2028) & (US$ Million)
Table 14. Global Antihyperuricemic Agents Revenue Market Share by Region (2023-2028)
Table 15. Global Antihyperuricemic Agents Sales by Manufacturers (2017-2022) & (K Units)
Table 16. Global Antihyperuricemic Agents Sales Share by Manufacturers (2017-2022)
Table 17. Global Antihyperuricemic Agents Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 18. Global Antihyperuricemic Agents Revenue Share by Manufacturers (2017-2022)
Table 19. Antihyperuricemic Agents Price by Manufacturers (2017-2022) &(US$/Unit)
Table 20. Global Antihyperuricemic Agents Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 21. Global Antihyperuricemic Agents by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antihyperuricemic Agents as of 2021)
Table 22. Antihyperuricemic Agents Manufacturing Base Distribution and Headquarters
Table 23. Manufacturers Antihyperuricemic Agents Product Offered
Table 24. Date of Manufacturers Enter into Antihyperuricemic Agents Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Antihyperuricemic Agents Sales by Type (2017-2022) & (K Units)
Table 27. Global Antihyperuricemic Agents Sales by Type (2023-2028) & (K Units)
Table 28. Global Antihyperuricemic Agents Sales Share by Type (2017-2022)
Table 29. Global Antihyperuricemic Agents Sales Share by Type (2023-2028)
Table 30. Global Antihyperuricemic Agents Revenue by Type (2017-2022) & (US$ Million)
Table 31. Global Antihyperuricemic Agents Revenue by Type (2023-2028) & (US$ Million)
Table 32. Global Antihyperuricemic Agents Revenue Share by Type (2017-2022)
Table 33. Global Antihyperuricemic Agents Revenue Share by Type (2023-2028)
Table 34. Antihyperuricemic Agents Price by Type (2017-2022) & (US$/Unit)
Table 35. Global Antihyperuricemic Agents Price Forecast by Type (2023-2028) & (US$/Unit)
Table 36. Global Antihyperuricemic Agents Sales by Distribution Channel (2017-2022) & (K Units)
Table 37. Global Antihyperuricemic Agents Sales by Distribution Channel (2023-2028) & (K Units)
Table 38. Global Antihyperuricemic Agents Sales Share by Distribution Channel (2017-2022)
Table 39. Global Antihyperuricemic Agents Sales Share by Distribution Channel (2023-2028)
Table 40. Global Antihyperuricemic Agents Revenue by Distribution Channel (2017-2022) & (US$ Million)
Table 41. Global Antihyperuricemic Agents Revenue by Distribution Channel (2023-2028) & (US$ Million)
Table 42. Global Antihyperuricemic Agents Revenue Share by Distribution Channel (2017-2022)
Table 43. Global Antihyperuricemic Agents Revenue Share by Distribution Channel (2023-2028)
Table 44. Antihyperuricemic Agents Price by Distribution Channel (2017-2022) & (US$/Unit)
Table 45. Global Antihyperuricemic Agents Price Forecast by Distribution Channel (2023-2028) & (US$/Unit)
Table 46. North America Antihyperuricemic Agents Sales by Type (2017-2022) & (K Units)
Table 47. North America Antihyperuricemic Agents Sales by Type (2023-2028) & (K Units)
Table 48. North America Antihyperuricemic Agents Revenue by Type (2017-2022) & (US$ Million)
Table 49. North America Antihyperuricemic Agents Revenue by Type (2023-2028) & (US$ Million)
Table 50. North America Antihyperuricemic Agents Sales by Distribution Channel (2017-2022) & (K Units)
Table 51. North America Antihyperuricemic Agents Sales by Distribution Channel (2023-2028) & (K Units)
Table 52. North America Antihyperuricemic Agents Revenue by Distribution Channel (2017-2022) & (US$ Million)
Table 53. North America Antihyperuricemic Agents Revenue by Distribution Channel (2023-2028) & (US$ Million)
Table 54. North America Antihyperuricemic Agents Sales by Country (2017-2022) & (K Units)
Table 55. North America Antihyperuricemic Agents Sales by Country (2023-2028) & (K Units)
Table 56. North America Antihyperuricemic Agents Revenue by Country (2017-2022) & (US$ Million)
Table 57. North America Antihyperuricemic Agents Revenue by Country (2023-2028) & (US$ Million)
Table 58. Europe Antihyperuricemic Agents Sales by Type (2017-2022) & (K Units)
Table 59. Europe Antihyperuricemic Agents Sales by Type (2023-2028) & (K Units)
Table 60. Europe Antihyperuricemic Agents Revenue by Type (2017-2022) & (US$ Million)
Table 61. Europe Antihyperuricemic Agents Revenue by Type (2023-2028) & (US$ Million)
Table 62. Europe Antihyperuricemic Agents Sales by Distribution Channel (2017-2022) & (K Units)
Table 63. Europe Antihyperuricemic Agents Sales by Distribution Channel (2023-2028) & (K Units)
Table 64. Europe Antihyperuricemic Agents Revenue by Distribution Channel (2017-2022) & (US$ Million)
Table 65. Europe Antihyperuricemic Agents Revenue by Distribution Channel (2023-2028) & (US$ Million)
Table 66. Europe Antihyperuricemic Agents Sales by Country (2017-2022) & (K Units)
Table 67. Europe Antihyperuricemic Agents Sales by Country (2023-2028) & (K Units)
Table 68. Europe Antihyperuricemic Agents Revenue by Country (2017-2022) & (US$ Million)
Table 69. Europe Antihyperuricemic Agents Revenue by Country (2023-2028) & (US$ Million)
Table 70. Asia Pacific Antihyperuricemic Agents Sales by Type (2017-2022) & (K Units)
Table 71. Asia Pacific Antihyperuricemic Agents Sales by Type (2023-2028) & (K Units)
Table 72. Asia Pacific Antihyperuricemic Agents Revenue by Type (2017-2022) & (US$ Million)
Table 73. Asia Pacific Antihyperuricemic Agents Revenue by Type (2023-2028) & (US$ Million)
Table 74. Asia Pacific Antihyperuricemic Agents Sales by Distribution Channel (2017-2022) & (K Units)
Table 75. Asia Pacific Antihyperuricemic Agents Sales by Distribution Channel (2023-2028) & (K Units)
Table 76. Asia Pacific Antihyperuricemic Agents Revenue by Distribution Channel (2017-2022) & (US$ Million)
Table 77. Asia Pacific Antihyperuricemic Agents Revenue by Distribution Channel (2023-2028) & (US$ Million)
Table 78. Asia Pacific Antihyperuricemic Agents Sales by Region (2017-2022) & (K Units)
Table 79. Asia Pacific Antihyperuricemic Agents Sales by Region (2023-2028) & (K Units)
Table 80. Asia Pacific Antihyperuricemic Agents Revenue by Region (2017-2022) & (US$ Million)
Table 81. Asia Pacific Antihyperuricemic Agents Revenue by Region (2023-2028) & (US$ Million)
Table 82. Latin America Antihyperuricemic Agents Sales by Type (2017-2022) & (K Units)
Table 83. Latin America Antihyperuricemic Agents Sales by Type (2023-2028) & (K Units)
Table 84. Latin America Antihyperuricemic Agents Revenue by Type (2017-2022) & (US$ Million)
Table 85. Latin America Antihyperuricemic Agents Revenue by Type (2023-2028) & (US$ Million)
Table 86. Latin America Antihyperuricemic Agents Sales by Distribution Channel (2017-2022) & (K Units)
Table 87. Latin America Antihyperuricemic Agents Sales by Distribution Channel (2023-2028) & (K Units)
Table 88. Latin America Antihyperuricemic Agents Revenue by Distribution Channel (2017-2022) & (US$ Million)
Table 89. Latin America Antihyperuricemic Agents Revenue by Distribution Channel (2023-2028) & (US$ Million)
Table 90. Latin America Antihyperuricemic Agents Sales by Country (2017-2022) & (K Units)
Table 91. Latin America Antihyperuricemic Agents Sales by Country (2023-2028) & (K Units)
Table 92. Latin America Antihyperuricemic Agents Revenue by Country (2017-2022) & (US$ Million)
Table 93. Latin America Antihyperuricemic Agents Revenue by Country (2023-2028) & (US$ Million)
Table 94. Middle East and Africa Antihyperuricemic Agents Sales by Type (2017-2022) & (K Units)
Table 95. Middle East and Africa Antihyperuricemic Agents Sales by Type (2023-2028) & (K Units)
Table 96. Middle East and Africa Antihyperuricemic Agents Revenue by Type (2017-2022) & (US$ Million)
Table 97. Middle East and Africa Antihyperuricemic Agents Revenue by Type (2023-2028) & (US$ Million)
Table 98. Middle East and Africa Antihyperuricemic Agents Sales by Distribution Channel (2017-2022) & (K Units)
Table 99. Middle East and Africa Antihyperuricemic Agents Sales by Distribution Channel (2023-2028) & (K Units)
Table 100. Middle East and Africa Antihyperuricemic Agents Revenue by Distribution Channel (2017-2022) & (US$ Million)
Table 101. Middle East and Africa Antihyperuricemic Agents Revenue by Distribution Channel (2023-2028) & (US$ Million)
Table 102. Middle East and Africa Antihyperuricemic Agents Sales by Country (2017-2022) & (K Units)
Table 103. Middle East and Africa Antihyperuricemic Agents Sales by Country (2023-2028) & (K Units)
Table 104. Middle East and Africa Antihyperuricemic Agents Revenue by Country (2017-2022) & (US$ Million)
Table 105. Middle East and Africa Antihyperuricemic Agents Revenue by Country (2023-2028) & (US$ Million)
Table 106. Takeda Pharmaceuticals Corporation Information
Table 107. Takeda Pharmaceuticals Description and Major Businesses
Table 108. Takeda Pharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 109. Takeda Pharmaceuticals Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 110. Takeda Pharmaceuticals Recent Developments
Table 111. Hikma Corporation Information
Table 112. Hikma Description and Major Businesses
Table 113. Hikma Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 114. Hikma Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 115. Hikma Recent Developments
Table 116. Wockhardt Corporation Information
Table 117. Wockhardt Description and Major Businesses
Table 118. Wockhardt Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 119. Wockhardt Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 120. Wockhardt Recent Developments
Table 121. West Ward Pharmaceuticals Corporation Information
Table 122. West Ward Pharmaceuticals Description and Major Businesses
Table 123. West Ward Pharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 124. West Ward Pharmaceuticals Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 125. West Ward Pharmaceuticals Recent Developments
Table 126. Rhea Pharmaceutical Corporation Information
Table 127. Rhea Pharmaceutical Description and Major Businesses
Table 128. Rhea Pharmaceutical Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 129. Rhea Pharmaceutical Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 130. Rhea Pharmaceutical Recent Developments
Table 131. Medinova Corporation Information
Table 132. Medinova Description and Major Businesses
Table 133. Medinova Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 134. Medinova Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 135. Medinova Recent Developments
Table 136. Odan Laboratories Corporation Information
Table 137. Odan Laboratories Description and Major Businesses
Table 138. Odan Laboratories Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 139. Odan Laboratories Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 140. Odan Laboratories Recent Developments
Table 141. TEIJIN Corporation Information
Table 142. TEIJIN Description and Major Businesses
Table 143. TEIJIN Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 144. TEIJIN Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 145. TEIJIN Recent Developments
Table 146. Casper Pharma Corporation Information
Table 147. Casper Pharma Description and Major Businesses
Table 148. Casper Pharma Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 149. Casper Pharma Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 150. Casper Pharma Recent Developments
Table 151. Dr. Reddys Laboratories Corporation Information
Table 152. Dr. Reddys Laboratories Description and Major Businesses
Table 153. Dr. Reddys Laboratories Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 154. Dr. Reddys Laboratories Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 155. Dr. Reddys Laboratories Recent Developments
Table 156. Teva Corporation Information
Table 157. Teva Description and Major Businesses
Table 158. Teva Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 159. Teva Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 160. Teva Recent Developments
Table 161. Zydus Pharmaceuticals Corporation Information
Table 162. Zydus Pharmaceuticals Description and Major Businesses
Table 163. Zydus Pharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 164. Zydus Pharmaceuticals Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 165. Zydus Pharmaceuticals Recent Developments
Table 166. Mylan Corporation Information
Table 167. Mylan Description and Major Businesses
Table 168. Mylan Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 169. Mylan Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 170. Mylan Recent Developments
Table 171. Sun Pharmaceutical Corporation Information
Table 172. Sun Pharmaceutical Description and Major Businesses
Table 173. Sun Pharmaceutical Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 174. Sun Pharmaceutical Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 175. Sun Pharmaceutical Recent Developments
Table 176. APOTEX Corporation Information
Table 177. APOTEX Description and Major Businesses
Table 178. APOTEX Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 179. APOTEX Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 180. APOTEX Recent Developments
Table 181. NorthStar Healthcare Corporation Information
Table 182. NorthStar Healthcare Description and Major Businesses
Table 183. NorthStar Healthcare Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 184. NorthStar Healthcare Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 185. NorthStar Healthcare Recent Developments
Table 186. Ipca Laboratories Corporation Information
Table 187. Ipca Laboratories Description and Major Businesses
Table 188. Ipca Laboratories Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 189. Ipca Laboratories Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 190. Ipca Laboratories Recent Developments
Table 191. Accord Healthcare Corporation Information
Table 192. Accord Healthcare Description and Major Businesses
Table 193. Accord Healthcare Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 194. Accord Healthcare Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 195. Accord Healthcare Recent Developments
Table 196. Gentec Pharmaceutical Group Corporation Information
Table 197. Gentec Pharmaceutical Group Description and Major Businesses
Table 198. Gentec Pharmaceutical Group Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 199. Gentec Pharmaceutical Group Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 200. Gentec Pharmaceutical Group Recent Developments
Table 201. Indoco Remedies Corporation Information
Table 202. Indoco Remedies Description and Major Businesses
Table 203. Indoco Remedies Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 204. Indoco Remedies Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 205. Indoco Remedies Recent Developments
Table 206. Lupin Corporation Information
Table 207. Lupin Description and Major Businesses
Table 208. Lupin Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 209. Lupin Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 210. Lupin Recent Developments
Table 211. Waterstone Pharmaceuticals Corporation Information
Table 212. Waterstone Pharmaceuticals Description and Major Businesses
Table 213. Waterstone Pharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 214. Waterstone Pharmaceuticals Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 215. Waterstone Pharmaceuticals Recent Developments
Table 216. ALP Pharm Corporation Information
Table 217. ALP Pharm Description and Major Businesses
Table 218. ALP Pharm Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 219. ALP Pharm Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 220. ALP Pharm Recent Developments
Table 221. Jiangsu Hengrui Medicine Corporation Information
Table 222. Jiangsu Hengrui Medicine Description and Major Businesses
Table 223. Jiangsu Hengrui Medicine Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 224. Jiangsu Hengrui Medicine Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 225. Jiangsu Hengrui Medicine Recent Developments
Table 226. Jiangsu Wanbang Biopharmaceuticals Corporation Information
Table 227. Jiangsu Wanbang Biopharmaceuticals Description and Major Businesses
Table 228. Jiangsu Wanbang Biopharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 229. Jiangsu Wanbang Biopharmaceuticals Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 230. Jiangsu Wanbang Biopharmaceuticals Recent Developments
Table 231. Hangzhou Zhuyangxin Pharmaceutical Corporation Information
Table 232. Hangzhou Zhuyangxin Pharmaceutical Description and Major Businesses
Table 233. Hangzhou Zhuyangxin Pharmaceutical Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 234. Hangzhou Zhuyangxin Pharmaceutical Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 235. Hangzhou Zhuyangxin Pharmaceutical Recent Developments
Table 236. YiChang HEC ChangJiang Pharmaceutical Corporation Information
Table 237. YiChang HEC ChangJiang Pharmaceutical Description and Major Businesses
Table 238. YiChang HEC ChangJiang Pharmaceutical Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 239. YiChang HEC ChangJiang Pharmaceutical Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 240. YiChang HEC ChangJiang Pharmaceutical Recent Developments
Table 241. KPC Pharmaceuticals Corporation Information
Table 242. KPC Pharmaceuticals Description and Major Businesses
Table 243. KPC Pharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 244. KPC Pharmaceuticals Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 245. KPC Pharmaceuticals Recent Developments
Table 246. Tonghua Limin Corporation Information
Table 247. Tonghua Limin Description and Major Businesses
Table 248. Tonghua Limin Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 249. Tonghua Limin Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 250. Tonghua Limin Recent Developments
Table 251. Beijing Jialin Pharmaceutical Corporation Information
Table 252. Beijing Jialin Pharmaceutical Description and Major Businesses
Table 253. Beijing Jialin Pharmaceutical Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 254. Beijing Jialin Pharmaceutical Antihyperuricemic Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 255. Beijing Jialin Pharmaceutical Recent Developments
Table 256. Key Raw Materials Lists
Table 257. Raw Materials Key Suppliers Lists
Table 258. Antihyperuricemic Agents Distributors List
Table 259. Antihyperuricemic Agents Customers List
Table 260. Antihyperuricemic Agents Market Trends
Table 261. Antihyperuricemic Agents Market Drivers
Table 262. Antihyperuricemic Agents Market Challenges
Table 263. Antihyperuricemic Agents Market Restraints
Table 264. Research Programs/Design for This Report
Table 265. Key Data Information from Secondary Sources
Table 266. Key Data Information from Primary Sources
List of Figures
Figure 1. Antihyperuricemic Agents Product Picture
Figure 3. Global Antihyperuricemic Agents Market Share by Type in 2021 & 2028
Figure 3. Inhibit Uric Acid Production Agents Product Picture
Figure 4. Promote Uric Acid Excretion Agents Product Picture
Figure 5. Others Product Picture
Figure 6. Global Antihyperuricemic Agents Market Share by Distribution Channel in 2021 & 2028
Figure 7. Hospital Pharmacies
Figure 8. Retail Pharmacies
Figure 9. Online Pharmacies
Figure 10. Antihyperuricemic Agents Report Years Considered
Figure 11. Global Antihyperuricemic Agents Sales 2017-2028 (K Units)
Figure 12. Global Antihyperuricemic Agents Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 13. Global Antihyperuricemic Agents Revenue 2017-2028 (US$ Million)
Figure 14. Global Antihyperuricemic Agents Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 15. Global Antihyperuricemic Agents Sales Market Share by Region (2017-2022)
Figure 16. Global Antihyperuricemic Agents Sales Market Share by Region (2023-2028)
Figure 17. North America Antihyperuricemic Agents Sales YoY (2017-2028) & (K Units)
Figure 18. North America Antihyperuricemic Agents Revenue YoY (2017-2028) & (US$ Million)
Figure 19. Europe Antihyperuricemic Agents Sales YoY (2017-2028) & (K Units)
Figure 20. Europe Antihyperuricemic Agents Revenue YoY (2017-2028) & (US$ Million)
Figure 21. Asia-Pacific Antihyperuricemic Agents Sales YoY (2017-2028) & (K Units)
Figure 22. Asia-Pacific Antihyperuricemic Agents Revenue YoY (2017-2028) & (US$ Million)
Figure 23. Latin America Antihyperuricemic Agents Sales YoY (2017-2028) & (K Units)
Figure 24. Latin America Antihyperuricemic Agents Revenue YoY (2017-2028) & (US$ Million)
Figure 25. Middle East & Africa Antihyperuricemic Agents Sales YoY (2017-2028) & (K Units)
Figure 26. Middle East & Africa Antihyperuricemic Agents Revenue YoY (2017-2028) & (US$ Million)
Figure 27. The Antihyperuricemic Agents Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 28. The Top 5 and 10 Largest Manufacturers of Antihyperuricemic Agents in the World: Market Share by Antihyperuricemic Agents Revenue in 2021
Figure 29. Global Antihyperuricemic Agents Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 30. Global Antihyperuricemic Agents Sales Market Share by Type (2017-2028)
Figure 31. Global Antihyperuricemic Agents Revenue Market Share by Type (2017-2028)
Figure 32. Global Antihyperuricemic Agents Sales Market Share by Distribution Channel (2017-2028)
Figure 33. Global Antihyperuricemic Agents Revenue Market Share by Distribution Channel (2017-2028)
Figure 34. North America Antihyperuricemic Agents Sales Market Share by Type (2017-2028)
Figure 35. North America Antihyperuricemic Agents Revenue Market Share by Type (2017-2028)
Figure 36. North America Antihyperuricemic Agents Sales Market Share by Distribution Channel (2017-2028)
Figure 37. North America Antihyperuricemic Agents Revenue Market Share by Distribution Channel (2017-2028)
Figure 38. North America Antihyperuricemic Agents Sales Share by Country (2017-2028)
Figure 39. North America Antihyperuricemic Agents Revenue Share by Country (2017-2028)
Figure 40. United States Antihyperuricemic Agents Revenue (2017-2028) & (US$ Million)
Figure 41. Canada Antihyperuricemic Agents Revenue (2017-2028) & (US$ Million)
Figure 42. Europe Antihyperuricemic Agents Sales Market Share by Type (2017-2028)
Figure 43. Europe Antihyperuricemic Agents Revenue Market Share by Type (2017-2028)
Figure 44. Europe Antihyperuricemic Agents Sales Market Share by Distribution Channel (2017-2028)
Figure 45. Europe Antihyperuricemic Agents Revenue Market Share by Distribution Channel (2017-2028)
Figure 46. Europe Antihyperuricemic Agents Sales Share by Country (2017-2028)
Figure 47. Europe Antihyperuricemic Agents Revenue Share by Country (2017-2028)
Figure 48. Germany Antihyperuricemic Agents Revenue (2017-2028) & (US$ Million)
Figure 49. France Antihyperuricemic Agents Revenue (2017-2028) & (US$ Million)
Figure 50. U.K. Antihyperuricemic Agents Revenue (2017-2028) & (US$ Million)
Figure 51. Italy Antihyperuricemic Agents Revenue (2017-2028) & (US$ Million)
Figure 52. Russia Antihyperuricemic Agents Revenue (2017-2028) & (US$ Million)
Figure 53. Asia Pacific Antihyperuricemic Agents Sales Market Share by Type (2017-2028)
Figure 54. Asia Pacific Antihyperuricemic Agents Revenue Market Share by Type (2017-2028)
Figure 55. Asia Pacific Antihyperuricemic Agents Sales Market Share by Distribution Channel (2017-2028)
Figure 56. Asia Pacific Antihyperuricemic Agents Revenue Market Share by Distribution Channel (2017-2028)
Figure 57. Asia Pacific Antihyperuricemic Agents Sales Share by Region (2017-2028)
Figure 58. Asia Pacific Antihyperuricemic Agents Revenue Share by Region (2017-2028)
Figure 59. China Antihyperuricemic Agents Revenue (2017-2028) & (US$ Million)
Figure 60. Japan Antihyperuricemic Agents Revenue (2017-2028) & (US$ Million)
Figure 61. South Korea Antihyperuricemic Agents Revenue (2017-2028) & (US$ Million)
Figure 62. India Antihyperuricemic Agents Revenue (2017-2028) & (US$ Million)
Figure 63. Australia Antihyperuricemic Agents Revenue (2017-2028) & (US$ Million)
Figure 64. China Taiwan Antihyperuricemic Agents Revenue (2017-2028) & (US$ Million)
Figure 65. Indonesia Antihyperuricemic Agents Revenue (2017-2028) & (US$ Million)
Figure 66. Thailand Antihyperuricemic Agents Revenue (2017-2028) & (US$ Million)
Figure 67. Malaysia Antihyperuricemic Agents Revenue (2017-2028) & (US$ Million)
Figure 68. Latin America Antihyperuricemic Agents Sales Market Share by Type (2017-2028)
Figure 69. Latin America Antihyperuricemic Agents Revenue Market Share by Type (2017-2028)
Figure 70. Latin America Antihyperuricemic Agents Sales Market Share by Distribution Channel (2017-2028)
Figure 71. Latin America Antihyperuricemic Agents Revenue Market Share by Distribution Channel (2017-2028)
Figure 72. Latin America Antihyperur

---